Company intelligence / Profile preview
VesiCURE Therapeutics
Suzhou（Suzhou Industrial Park）, Jiangsu Province, Chinavesicure.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
VesiCURE has developed a proprietary exosome-based drug delivery platform ("modEXO") to enable targeted therapies for oncology and inflammatory/immune conditions. The company’s pipeline includes multiple preclinical-stage assets targeting cancers such as lung cancer, solid tumors, liver disease, and immune/inflammatory disorders. No clinical results have been reported yet.
- Therapeutic areas
- ImmunologyOncologyPulmonologyGastroenterology
- Modalities
- Exosomes / extracellular vesicles (EVs)siRNA / nucleic acidsOligonucleotidesTherapeutic vaccines
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on VesiCURE Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VesiCURE Therapeutics.